ASPI: Proprietary enrichment tech, global expansion, and strong financials drive >$300M 2031 EBITDA target
Category: Business
Share
Archive
Like
Four operating divisions are scaling rapidly, with proprietary enrichment technologies proven at commercial scale and a strong financial position. Key milestones include new plant launches, global radiopharmacy expansion, and strategic partnerships in nuclear fuels and advanced materials. EBITDA is targeted to exceed $300M by 2031, with significant upside potential.
Original document: ASP Isotopes Inc. [ASPI] Slides Release — Sep. 8 2026
A note on cookies
Newshunt uses essential cookies to keep you signed in and to remember your language and country, so the site works the way you expect. With your permission, we'd also like to use analytics cookies to understand how people use Newshunt and improve it over time.
Accepting only affects analytics. To learn more, view our Privacy Policy or Terms & Conditions.
(0)Comments